CATALYST PHARMACEUTICALS, INC. (CPRX) Cash flow
Market cap
$3.8B
P/E ratio
18.6x
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 153,989 | 164,878 | 187,361 | - | - | - | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | 6 | 6 | 6 | 777,969 | 2 | 2 | 2 | 4 | 4 | 6 | 6 | 8 | 14 | 22 | 25 |
| Cash from operations | -4,985,049 | -5,140,366 | -9,875,674 | -12,941,783 | -18,015,221 | -17,963,503 | -13,742,572 | -25,704,406 | 35 | 45 | 60 | 116 | 144 | 240 | 209 |
| Capital expenditures | -102,826 | -155,208 | -164,640 | -57,323 | -23,465 | -96,061 | - | -92,018 | -19,369 | -11,398 | -1 | -0 | -0 | -1 | -0 |
| Cash from investing | -3,620 | -14,059,651 | -7,496,801 | -8,741,030 | -6,499 | 4 | -3,958 | -15,526,011 | 37 | -5,011,398 | -11 | 9 | -294 | -1 | -0 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | 12 | 7 | - | - | 25 |
| Cash from financing | 37 | 52 | 70 | 29 | 37 | 68,986 | 57 | 293,115 | 1 | 701,933 | -8 | 2 | -11 | 141 | -17 |
| Free cash flow | - | ||||||||||||||
| FCF margin (%) | - | - | - | - | - | - | - |